High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM)

Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy

(2014) Olga Moshkin et al.   Hormones-International Journal of Endocrinology and Metabolism

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

(2013) Robert L. Fine et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Approach to the Cushing's Disease Patient With Persistent/Recurrent Hypercortisolism After Pituitary Surgery

(2013) Xavier Bertagna et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Silent or Subclinical Corticotroph Pituitary Macroadenoma Transforming Into Cushing Disease

(2012) Eugen Melcescu et al.   NEUROSURGERY

Treatment of Multiple Endocrine Neoplasia 1/2 Tumors: Case Report and Review of the Literature

(2012) Anthony P. Gulati et al.   ONCOLOGY

Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature

(2011) A. K. Annamalai et al.   Pituitary

Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review

(2011) Lorenzo Curtò et al.   TheScientificWorldJOURNAL

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

(2010) Jonathan R. Strosberg et al.   CANCER

SOM230 (Pasireotide) and Temozolomide Achieve Sustained Control of Tumour Progression and ACTH Secretion in Pituitary Carcinoma with Widespread Metastases

(2010) H. Bode et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Temozolomide for corticotroph pituitary adenomas refractory to standard therapy

(2010) Troy H. Dillard et al.   Pituitary

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

(2009) C Hagen et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A novel use of temozolomide in a patient with malignant prolactinoma

(2009) Stephen Byrne et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor

(2009) Marie S. Thearle et al.   Pituitary

Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas

(2008) Casilda Balmaceda et al.   CANCER

O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

(2008) M. H. Kulke et al.   CLINICAL CANCER RESEARCH

Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours

(2008) Ann I. McCormack et al.   CLINICAL ENDOCRINOLOGY